Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 5,500 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 5,500 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $27.65, for a total transaction of $152,075.00. Following the sale, the insider now owns 75,294 shares of the company’s stock, valued at $2,081,879.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Catriona Yale also recently made the following trade(s):

• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total transaction of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.52, for a total transaction of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total transaction of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.53, for a total transaction of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Stock Up 1.0 %

Shares of AKRO traded up $0.29 on Monday, hitting $28.37. 474,393 shares of the stock traded hands, compared to its average volume of 931,884. The company has a market capitalization of $1.96 billion, a PE ratio of -8.87 and a beta of -0.26. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. The business has a 50 day simple moving average of $26.33 and a 200 day simple moving average of $23.87. Akero Therapeutics, Inc. has a one year low of $11.25 and a one year high of $51.24.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.09. As a group, equities analysts forecast that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its position in Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares during the period. Quarry LP grew its position in Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after purchasing an additional 500 shares during the period. Quest Partners LLC bought a new stake in Akero Therapeutics in the 4th quarter worth approximately $75,000. Headlands Technologies LLC grew its position in Akero Therapeutics by 253.5% in the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock worth $107,000 after purchasing an additional 3,024 shares during the period. Finally, Ameritas Investment Partners Inc. grew its position in Akero Therapeutics by 20.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after purchasing an additional 1,030 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have commented on AKRO. Cantor Fitzgerald restated an “overweight” rating on shares of Akero Therapeutics in a report on Thursday, June 20th. Wolfe Research started coverage on shares of Akero Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research note on Tuesday, September 17th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Akero Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $41.13.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.